TY - JOUR
T1 - Efficacy and tolerability of 100 mg of lasmiditan for migraine
T2 - A multi-center, prospective observational real-world study in Japan
AU - Ishii, Ryotaro
AU - Ishizuchi, Kei
AU - Watanabe, Narumi
AU - Fukazawa, Ryosuke
AU - Trivedi, Meesha
AU - Nakahara, Jin
AU - Takizawa, Tsubasa
N1 - Publisher Copyright:
© International Headache Society 2024.
PY - 2024/6
Y1 - 2024/6
N2 - Background: Real-world data on the effectiveness and safety of lasmiditan, a new medication for acute migraine attacks, is necessary. Methods: We performed a prospective, observational, multi-center, real-world study. A total of 48 patients with migraine (44 females, 44.6 ± 12.9 years old) were included in this study. Results: Twenty-three patients (47.9%) reported they were headache-free two hours after taking lasmiditan and were categorized into the responder group. In total, 44 patients (91.7%) experienced at least one side effect within two hours of taking the medication. Dizziness, somnolence, malaise, nausea, and palpitations were reported by 56.3% (n = 27), 45.8% (n = 22), 37.5% (n = 18), 20.8% (n = 10), and 14.6% (n = 7) of patients respectively. Of 48 patients, 20 (41.7%) indicated that they preferred lasmiditan to their previous acute treatment. There were no predictive factors for efficacy. Conclusion: This real-world study demonstrated the efficacy and safety of lasmiditan. More than 90% of patients experienced side effects from lasmiditan. Approximately 40% of patients preferred lasmiditan despite the occurrence of side effects.
AB - Background: Real-world data on the effectiveness and safety of lasmiditan, a new medication for acute migraine attacks, is necessary. Methods: We performed a prospective, observational, multi-center, real-world study. A total of 48 patients with migraine (44 females, 44.6 ± 12.9 years old) were included in this study. Results: Twenty-three patients (47.9%) reported they were headache-free two hours after taking lasmiditan and were categorized into the responder group. In total, 44 patients (91.7%) experienced at least one side effect within two hours of taking the medication. Dizziness, somnolence, malaise, nausea, and palpitations were reported by 56.3% (n = 27), 45.8% (n = 22), 37.5% (n = 18), 20.8% (n = 10), and 14.6% (n = 7) of patients respectively. Of 48 patients, 20 (41.7%) indicated that they preferred lasmiditan to their previous acute treatment. There were no predictive factors for efficacy. Conclusion: This real-world study demonstrated the efficacy and safety of lasmiditan. More than 90% of patients experienced side effects from lasmiditan. Approximately 40% of patients preferred lasmiditan despite the occurrence of side effects.
KW - Japan
KW - efficacy
KW - lasmiditan
KW - migraine
KW - real-world data
KW - tolerability
UR - http://www.scopus.com/inward/record.url?scp=85195627510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85195627510&partnerID=8YFLogxK
U2 - 10.1177/03331024241258695
DO - 10.1177/03331024241258695
M3 - Article
C2 - 38859749
AN - SCOPUS:85195627510
SN - 0333-1024
VL - 44
JO - Cephalalgia
JF - Cephalalgia
IS - 6
ER -